Gastric cancer immunotherapy is still being explored

Share This Post

Gastric cancer immunotherapy is still an exciting research area, especially the pd-1 inhibitors pembrolizumab (Keytruda) and nivolumab (Nivolumab, Opdivo).

In the Phase III ONO-4538-12 trial, nivolumab third-line or follow-up treatment reduced the risk of death in patients with advanced gastric cancer or gastroesophageal junction (GEJ) cancer by 37% compared with patients using placebo. The median overall survival rate (OS) was 5.32 months, compared with 4.14 months in the placebo group.

In September 2017, the FDA approved Pembrolizumab for the treatment of PD-L1-positive advanced patients who had received second-line or more treatment of gastric cancer, including fluopyridine and platinum, and if applicable, HER-2 / neu targeted therapy .

However, exploring immune checkpoint inhibitors remains a challenge. In the phase III keynote-061 trial, Pembrolizumab did not improve the survival rate of patients with advanced gastric cancer (or GEJ) in second-line treatment. PD-1 inhibitors also failed to demonstrate a significant improvement in progression-free survival (PFS). The response rate of all patients was 10%, and the 1-year survival rate was approximately 25%, which was similar to the phase III results of nivolumab. However, these patients have undergone PD-L1 genetic testing, and the response rate of PD-L1 positive patients is 15%, while the negative rate is only 5%.

Pembrolizumab is approved for microsatellite unstable (MSI-H) tumors. In colon cancer, anti-PD-1 drugs are very active in msi-h tumors, with a response rate of 30% or 50%. In addition, valuable data have also been obtained in other msi-h tumors, with ≥50% of patients responding. Even in a large phase II extended clinical trial, 7 patients with MSI-H responded to 4 of them. Pembrolizumab has now been approved for PD-L1 positive MSI-H tumors and chemotherapy-resistant gastric cancer (or GEJ).

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy